These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 27289263)
1. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab. Ghazali N; Parker L; Settle K; Lubek JE Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263 [TBL] [Abstract][Full Text] [Related]
2. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571 [TBL] [Abstract][Full Text] [Related]
3. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317 [TBL] [Abstract][Full Text] [Related]
5. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Krishnamurthy J; Krishnamurty DM; Baker JJ; Zhen W; Lydiatt D; Ganti AK Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450 [TBL] [Abstract][Full Text] [Related]
6. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Sharon E; Kelly RJ; Szabo E Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363 [TBL] [Abstract][Full Text] [Related]
7. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325 [TBL] [Abstract][Full Text] [Related]
8. The role of trastuzumab in the management of salivary ductal carcinomas. Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912 [TBL] [Abstract][Full Text] [Related]
9. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212 [TBL] [Abstract][Full Text] [Related]
11. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy]. Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650 [TBL] [Abstract][Full Text] [Related]
12. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma. Taha T; Billan S Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606 [TBL] [Abstract][Full Text] [Related]
13. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Ruzich JC; Ciesla MC; Clark JI Head Neck; 2002 Apr; 24(4):406-10. PubMed ID: 11933184 [TBL] [Abstract][Full Text] [Related]
14. Salivary gland tumors in children: a retrospective clinical review. Varan A; Akyüz C; Ataş E; Yücel T; Aydın B; Yalçın B; Kutluk T; Büyükpamukçu M Pediatr Hematol Oncol; 2014 Nov; 31(8):681-6. PubMed ID: 25247345 [TBL] [Abstract][Full Text] [Related]
15. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature. Firwana B; Atassi B; Hasan R; Hasan N; Sukari A Avicenna J Med; 2012 Jul; 2(3):71-73. PubMed ID: 23826550 [TBL] [Abstract][Full Text] [Related]
18. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers. Haigh JE; Patel K; Rack S; Jiménez-Labaig P; Betts G; Harrington KJ; Metcalf R Curr Oncol; 2024 Sep; 31(9):5652-5661. PubMed ID: 39330047 [TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Sousa LG; Wang K; Torman D; Binks BJ; Rubin ML; Andersen CR; Lewis WE; Rivera MJ; Kaya D; El-Naggar AK; Hanna EY; Esmaeli B; Frank SJ; Bell D; Glisson BS; Rodon J; Meric-Bernstam F; Lee JJ; Ferrarotto R Cancer; 2022 Feb; 128(3):509-518. PubMed ID: 34661906 [TBL] [Abstract][Full Text] [Related]
20. Neck dissection findings in primary head and neck high-grade adenocarcinoma. Sheahan P; Byrne M; Hafidh M; Toner M; Simon C J Laryngol Otol; 2004 Jul; 118(7):532-6. PubMed ID: 15318960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]